Abbott introduces two-in-one glucose ketone sensor: Can ABT recover above the MA-50?

Abbott introduces two-in-one glucose ketone sensor: Can ABT recover above the MA-50?
Abbott stock edges lower to $103.82

Abbott introduced a new dual glucose and ketone sensing technology for diabetes management. The stock edges lower on the day, trading at $103.82.

ABT price prediction
24H -0.13%
$103.83
48H 0.07%
$104.04
7D -0.98%
$102.95
1M 3.51%
$107.62
3M 3.78%
$107.9
6M -14.45%
$88.95
12M -19.21%
$84
Current price: $103.97 -0.5200 0.50%
Closed 11/19
Daily range 103.85 Arrow from to Icon 105.60
Weekly range 103.22 Arrow from to Icon 110.43
Loading...

Highlights

  • Abbott unveiled a dual continuous glucose and ketone monitoring device for diabetes that received CES Innovation Awards recognition.
  • 89 of 110 analysts rate Abbott stock a buy, and the median price target is $120.
  • Abbott stock edges lower on the day, trading at $103.82.

Abbott introduced a two-in-one continuous glucose ketone sensing technology aimed at people living with diabetes. The device was recognized as a CES Innovation Awards Honoree. The product is intended to offer a more complete approach to diabetes care by allowing users to monitor both glucose and ketone levels.

Downside contained as shares stall at resistance below key averages

Price lost the MA-50 at $103.88 during the session after closing above it. Shares of Abbott are sitting right at resistance from that level, within a split daily structure where price remains below the MA-20 and MA-50 but above the MA-200. Stoch RSI is in oversold territory, a stretched reading that limits room for further downside. The trading action has been contained within a narrow range over the past week.

Odds tilt slightly to the downside as $103.88 level draws focus

Traders should watch whether price can close above $103.88 to confirm buyers are willing to follow through. The price briefly moved above that level but closed below it by the end of the session. Even so, for the coming trading week, there is a 48% chance of upside and a 52% chance of downside, with shares expected to trade between $100.59 and $107.04. A move above $103.88 would confirm acceptance, while a drop below $103.22 would indicate the move is being faded. On the weekly chart the longer-term picture stays negative.

Earlier, analysts noted that Abbott maintained a broadly bullish technical posture despite caution around near-term overbought conditions and the potential for a short-term pullback. The introduction of its new dual glucose and ketone sensor adds a significant development to the story, but with shares testing critical support, traders should closely monitor $103.22 as a potential tipping point for renewed downward momentum.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.